Gene Therapy Approaches Using Reproducible and Fully Penetrant Lentivirus-Mediated Endogenous Glioma Models
Animal models have proven invaluable for progress toward greater understanding of the etiology, pathogenesis, and genetics of a wide range of human diseases. The development of relevant brain tumor animal models is a critical resource for building our understanding of cancers that arise within the brain and for the development of novel therapies. The central role of these models is particularly apparent for gliomas, which are common and devastating primary brain tumors. Effective models accurately demonstrate pathological features and behavior that are analogous to the human disease. Models aim to develop tumors with high penetrance and low latency, features that are ideal for preclinical therapeutic development. Lentiviral vector-induced models fulfill these requirements while giving investigators excellent control over the genetic profile of resulting tumors. This flexibility is especially relevant in the context of recent advances in the understanding of the genetic lesions found in human grade IV glioma, glioblastoma multiforme (GBM). Further, these endogenous tumor models would be ideal for the testing of novel gene therapy strategies which could potentially be implemented in Phase 1 clinical trials for these devastating human brain cancers.
Key wordsAnimal model Lentivirus Glioma Glioblastoma Gene therapy p53 PDGF AKT HRAS
This work was supported by National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS) Grants 1UO1-NS052465, UO1-NS052465-S1, 1R21-NSO54143, 1RO1-NS057711, 1RO1-NS074387, MICHR Pilot R14 U040007, and BioInterfaces Institute, University of Michigan U042841 to M.G.C.; NIH/NINDS Grants 1RO1-NS054193, 1RO1-NS061107, 1RO1-NS082311, R21-NS084275, and M-Cube U036756 University of Michigan to P.R.L.; the Department of Neurosurgery, University of Michigan School of Medicine; the Michigan Institute for Clinical and Health Research, NIH UL1-TR000433; University of Michigan Cancer Biology Training Grant, NIH/NCI (National Cancer Institute) T32-CA009676; University of Michigan Training in Clinical and Basic Neuroscience, NIH/NINDS T32-NS007222; and the University of Michigan Medical Scientist Training Program, NIH/NIGMS (National Institute of General Medicine Sciences) T32-GM007863, and the National Institutes of Health through the University of Michigan’s Cancer Center Support Grant P30-CA046592. C.K. is supported by an NIH T32 training grant under Dr. James Ferrara (2-T32-HL-007622-26-A1). M.C. receives financial support from the National Council for Science and Technology (PIP 114-201101-00353, CONICET, Argentina). M.A.M.A. is supported by a doctoral fellowship from CONICET (Argentina). We are grateful to Dr. Karin Murasko for her academic leadership and D. Tomford and S. Napolitan for their superb administrative support.
- 25.Paxinos G, Watson C (1998) The rat atlas in stereotaxic coordinates. Elsevier Science & Technology Books. 256 pGoogle Scholar
- 26.Barcia C, Gerdes C, Xiong WD et al (2006) Immunological thresholds in neurological gene therapy: highly efficient elimination of transduced cells might be related to the specific formation of immunological synapses between T cells and virus-infected brain cells. Neuron Glia Biol 2:309–322PubMedCrossRefGoogle Scholar
- 31.Puntel M, Kroeger KM, Sanderson NS et al (2010) Gene tranfer into at brain using adenoviral vectors Curr Protoc Neurosci. 50:4.24:4.24:1–4.24.49Google Scholar